F2RL1 and Hepatic fibrosis: Pepducin PZ-235 was selected as a full PAR2 antagonist since this compound was effective in the inhibition of liver fibrosis, hepatocellular necrosis, reactive oxygen species production, steatosis, and inflammation in experimental NASH (68).